Yujuan Cao1, Xiaodong Wang1. 1. Department of Oncology, Peking University Shougang Hospital, Beijing, China.
Abstract
OBJECTIVE: To summarize the effects of molecular markers on the treatment decision and prognosis of colorectal cancer. BACKGROUND: Colorectal cancer is a highly heterogeneous disease. Even colorectal cancers of the same pathological type and clinical stage may have significant differences in treatment efficacy and prognosis. There are three main molecular mechanisms for the occurrence and development of colorectal cancer: chromosomal instability (CIN) pathway, microsatellite instability (MSI), and CpG island methylate phenotype (CIMP). There are multiple molecular markers distributed on each pathway. METHODS: We performed a literature search on the PubMed database for studies published in English (from the date of initiation of the database to the year of 2020) using the following subject terms: "colon cancer", "rectal cancer", "colorectal cancer", "molecular markers", "biomarkers", "treatment strategies", and "prognosis". CONCLUSIONS: The different expression states of molecular markers have a significant impact on the treatment decision and prognosis of colorectal cancer. Main colorectal cancer molecular markers include MSI and some important genes. Individualized treatments for tumors with different molecular phenotypes have improved the treatment effectiveness for colorectal cancer. The rational use of molecular markers is valuable for treatment decision-making and the prognosis of patients with colorectal cancer. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
OBJECTIVE: To summarize the effects of molecular markers on the treatment decision and prognosis of colorectal cancer. BACKGROUND: Colorectal cancer is a highly heterogeneous disease. Even colorectal cancers of the same pathological type and clinical stage may have significant differences in treatment efficacy and prognosis. There are three main molecular mechanisms for the occurrence and development of colorectal cancer: chromosomal instability (CIN) pathway, microsatellite instability (MSI), and CpG island methylate phenotype (CIMP). There are multiple molecular markers distributed on each pathway. METHODS: We performed a literature search on the PubMed database for studies published in English (from the date of initiation of the database to the year of 2020) using the following subject terms: "colon cancer", "rectal cancer", "colorectal cancer", "molecular markers", "biomarkers", "treatment strategies", and "prognosis". CONCLUSIONS: The different expression states of molecular markers have a significant impact on the treatment decision and prognosis of colorectal cancer. Main colorectal cancer molecular markers include MSI and some important genes. Individualized treatments for tumors with different molecular phenotypes have improved the treatment effectiveness for colorectal cancer. The rational use of molecular markers is valuable for treatment decision-making and the prognosis of patients with colorectal cancer. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Julien Taieb; Josep Tabernero; Enrico Mini; Fabien Subtil; Gunnar Folprecht; Jean-Luc Van Laethem; Josef Thaler; John Bridgewater; Lone Nørgård Petersen; Hélène Blons; Laurence Collette; Eric Van Cutsem; Philippe Rougier; Ramon Salazar; Laurent Bedenne; Jean-François Emile; Pierre Laurent-Puig; Come Lepage Journal: Lancet Oncol Date: 2014-06-11 Impact factor: 41.316
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Ki Young Chung; Jinru Shia; Nancy E Kemeny; Manish Shah; Gary K Schwartz; Archie Tse; Audrey Hamilton; Dorothy Pan; Deborah Schrag; Lawrence Schwartz; David S Klimstra; Daniel Fridman; David P Kelsen; Leonard B Saltz Journal: J Clin Oncol Date: 2005-01-27 Impact factor: 44.544
Authors: Murray B Resnick; Justin Routhier; Tamako Konkin; Edmond Sabo; Victor E Pricolo Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem Journal: N Engl J Med Date: 2004-07-22 Impact factor: 91.245
Authors: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier Journal: N Engl J Med Date: 2009-04-02 Impact factor: 91.245
Authors: Sabine Tejpar; Monica Bertagnolli; Fred Bosman; Heinz-Joseph Lenz; Levi Garraway; Frederic Waldman; Robert Warren; Andrea Bild; Denise Collins-Brennan; Hejin Hahn; D Paul Harkin; Richard Kennedy; Mohammad Ilyas; Hans Morreau; Vitali Proutski; Charles Swanton; Ian Tomlinson; Mauro Delorenzi; Roberto Fiocca; Eric Van Cutsem; Arnaud Roth Journal: Oncologist Date: 2010-03-29